Adicet Bio, Inc. (ACET) Financial Statements (2026 and earlier)

Company Profile

Business Address 131 DARTMOUTH STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments158,530176,303159,711257,656277,54494,614
Cash and cash equivalent38,91856,495159,711257,656277,54484,330
Short-term investments119,612119,808   10,284
Receivables342  4352142,731
Prepaid expense3384273732951,0211,185
Other current assets3204744573802363
Other undisclosed current assets1,3962,9321,7312,2723,6571,443
Total current assets:160,926180,136162,272261,038282,438100,336
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization1,022     
Operating lease, right-of-use asset10,92714,22817,42420,26920,35823,066
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization16,53222,52426,77728,71014,6432,790
Intangible asset, including goodwill, after accumulated amortization    19,46219,46220,089
Goodwill    19,46219,46220,089
Restricted cash and investments2,8722,903  1504,527
Other noncurrent assets764288221,2111,8871,837
Other undisclosed noncurrent assets      1,190
Total noncurrent assets:31,42940,08345,02369,65256,50053,499
TOTAL ASSETS:192,355220,219207,295330,690338,938153,835
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,59211,9659,15110,1387,7865,711
Employee-related liabilities✕✕✕✕✕4,0203,833
Accounts payable4,7394,8302,6254,4043,2631,552
Accrued liabilities5,8537,1356,5265,734503326
Deferred revenue     4,80513,980
Debt349     
Other undisclosed current liabilities10,5907,42710,1369,5693,7262,788
Total current liabilities:21,53119,39219,28719,70716,31722,479
Noncurrent Liabilities
Long-term debt and lease obligation642   19,37720,424
Finance lease, liability642     
Liabilities, other than long-term debt10,97214,21817,83318,645 125
Deferred income tax liabilities      125
Other liabilities 62116130114  
Operating lease, liability10,91014,10217,70318,53119,37720,424
Other undisclosed noncurrent liabilities     (19,262)980
Total noncurrent liabilities:11,61414,21817,83318,64519,49221,529
Total liabilities:33,14533,61037,12038,35235,80944,008
Equity
Equity, attributable to parent159,210186,609170,175292,338303,129109,827
Common stock1084442
Additional paid in capital773,795684,479550,943530,448471,449216,126
Accumulated other comprehensive income (loss)10216   24
Accumulated deficit(614,697)(497,894)(380,772)(238,114)(168,324)(106,325)
Total equity:159,210186,609170,175292,338303,129109,827
TOTAL LIABILITIES AND EQUITY:192,355220,219207,295330,690338,938153,835

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues67472771424,9909,73017,903
Revenue from related parties✕✕✕✕24,9909,73017,903
Sublease income674727714   
Net investment income      
Gross profit:67472771424,9909,73017,903
Operating expenses(122,114)(127,615)(152,038)(97,541)(71,163)(57,094)
Other undisclosed operating loss(674)(727)(714)   
Operating loss:(122,114)(127,615)(152,038)(72,551)(61,433)(39,191)
Nonoperating expense
(Other Nonoperating expense)		(430)(217)(573)(919)(606)(953)
Interest and debt expense(36) (25)(80)(176)(134)
Loss from continuing operations before equity method investments, income taxes:(122,580)(127,832)(152,636)(73,550)(62,215)(40,278)
Other undisclosed income from continuing operations before income taxes5,77710,7109,9783,76091785
Loss from continuing operations before income taxes:(116,803)(117,122)(142,658)(69,790)(62,124)(39,493)
Income tax benefit     1252,815
Loss from continuing operations:(116,803)(117,122)(142,658)(69,790)(61,999)(36,678)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(61,999)(36,678)
Net loss available to common stockholders, diluted:(116,803)(117,122)(142,658)(69,790)(61,999)(36,678)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(116,803)(117,122)(142,658)(69,790)(61,999)(36,678)
Other comprehensive income (loss)8616  (24)1
Comprehensive loss, net of tax, attributable to parent:(116,717)(117,106)(142,658)(69,790)(62,023)(36,677)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: